Benefit — PMC + label stance
What Snapshot-grade representation evidence saves you at PMC + labeling
PMC scope + label restrictions are negotiated. The sponsor's stance in that negotiation is set by what the sponsor knew, when the sponsor knew it, and what the sponsor did about it.
The three moments where it matters
- Pre-approval reviewer conversation. If the pivotal-trial representation gap becomes visible, FDA can require a PMC trial as a condition of approval. Snapshot evidence shifts the required scope.
- Labeling negotiation. Reviewers can add subgroup-restriction language when representation is weak. Sponsor-side monitoring evidence supports broader label claims.
- Post-approval RWE surfacing. Claims + EHR + registry data will eventually reveal underrepresented-subgroup outcomes. Dated in-trial evidence sets the response frame.
Dollar frame
PMC trial cost: $5M-$50M+ per program for a representation-driven PMC. Multi-PMC scenarios stack.
Label restriction cost: subgroup exclusions in labeling can reduce peak sales by 15-40% depending on indication + market. For a $500M/yr peak drug, that is $75M-$200M/yr in lifetime revenue.
Preventive discipline cost: $499 Snapshot. Dated evidence the sponsor detected + acted on the representation gap in-trial.
Who at your org cares
- Chief Commercial Officer — label + peak-sales impact
- VP Regulatory Affairs — PMC + labeling negotiation
- Chief Medical Officer — equity-of-access narrative
- Head of Real-World Evidence — RWE-comparison baseline
What "having it" looks like
Green: Snapshot on file. Sponsor detected + acted in-trial. PMC scope narrower, label broader, post-approval RWE conversation defensible.
Red: Representation gap surfaces post-approval via RWE. Sponsor learns of the pattern last. PMC + label restrictions expand.
$499. 3 business days.
Independent in-trial evidence of representation monitoring. The record that shifts PMC + label negotiation before RWE data lands.
Buy $499